Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple MyelomaSundar Jagannath, Thomas G Martin, Yi Lin, et al.
Nature Reviews. Nephrology|December 5, 2018
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research GroupNelson Leung, Frank Bridoux, Vecihi Batuman, et al.
Leukemia|January 27, 2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myelomaLuciano J Costa, Rahul Banerjee, Hira Mian, et al.
Nature Reviews. Nephrology|December 21, 2018
Publisher Correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research GroupNelson Leung, Frank Bridoux, Vecihi Batuman, et al.
The Lancet. Oncology|December 21, 2019
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.
The New England Journal of Medicine|December 9, 2024
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple MyelomaMeletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, et al.
Transplantation and Cellular Therapy|December 9, 2022
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN TrialsSaurabh Chhabra, Natalie Callander, Nicole L Watts, et al.
Blood Cancer Journal|April 22, 2024
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic riskNatalie S Callander, Rebecca Silbermann, Jonathan L Kaufman, et al.
Blood Advances|August 28, 2025
Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell LeukemiaGliceida M Galarza Fortuna, Lauren C Peres, Elena Nazarenko, et al.
Blood Cancer Journal|October 16, 2024
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myelomaGliceida Galarza Fortuna, Rahul Banerjee, Constanza Savid-Frontera, et al.
Pageof 10